Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura
- 26 November 1998
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 339 (22), 1585-1594
- https://doi.org/10.1056/nejm199811263392203
Abstract
Thrombotic thrombocytopenic purpura is a potentially fatal disease characterized by widespread platelet thrombi in the microcirculation. In the normal circulation, von Willebrand factor is cleaved by a plasma protease. We explored the hypothesis that a deficiency of this protease predisposes patients with thrombotic thrombocytopenic purpura to platelet thrombosis. We studied the activity of von Willebrand factor–cleaving protease and sought inhibitors of this protease in plasma from patients with acute thrombotic thrombocytopenic purpura, patients with other diseases, and normal control subjects. We also investigated the effect of shear stress on the ristocetin cofactor activity of purified von Willebrand factor in the cryosupernatant fraction of the plasma samples. Thirty-nine samples of plasma from 37 patients with acute thrombotic thrombocytopenic purpura had severe deficiency of von Willebrand factor–cleaving protease. No deficiency was detected in 16 samples of plasma from patients with thrombotic thrombocytopenic purpura in remission or in 74 plasma samples from normal subjects, randomly selected hospitalized patients or outpatients, or patients with hemolysis, thrombocytopenia, or thrombosis from other causes. Inhibitory activity against the protease was detected in 26 of the 39 plasma samples (67 percent) obtained during the acute phase of the disease. The inhibitors were IgG antibodies. Shear stress increased the ristocetin cofactor activity of von Willebrand factor in the cryosupernatant of plasma samples obtained during the acute phase, but decreased the activity in cryosupernatant of plasma from normal subjects. Inhibitory antibodies against von Willebrand factor–cleaving protease occur in patients with acute thrombotic thrombocytopenic purpura. A deficiency of this protease is likely to have a critical role in the pathogenesis of platelet thrombosis in this disease.Keywords
This publication has 38 references indexed in Scilit:
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 1998
- Increasing mortality from thrombotic thrombocytopenic purpura in the United States—analysis of national mortality data, 1968–1991American Journal of Hematology, 1995
- Anti‐CD36 antibodies in thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 1994
- HLA‐DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndromeAmerican Journal of Hematology, 1994
- Further characterization of platelet‐aggregating cysteine proteinase activity in thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 1994
- Comparison of Plasma Exchange with Plasma Infusion in the Treatment of Thrombotic Thrombocytopenic PurpuraThe New England Journal of Medicine, 1991
- Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma.JCI Insight, 1985
- Efficacy of several plasma components in a young boy with chronic thrombocytopenia and hemolytic anemia who responds repeatedly to normal plasma infusionsAmerican Journal of Hematology, 1984
- Unusually Large Plasma Factor VIII: von Willebrand Factor Multimers in Chronic Relapsing Thrombotic Thrombocytopenic PurpuraThe New England Journal of Medicine, 1982
- Immunologic and Other Factors in Thrombotic Thrombocytopenic Purpura (TTP)Seminars in Thrombosis and Hemostasis, 1980